Literature DB >> 9713831

TRH inactivation in the extracellular compartment: role of pyroglutamyl peptidase II.

J L Charli1, M A Vargas, M Cisneros, P de Gortari, M A Baeza, P Jasso, J Bourdais, L Peréz, R M Uribe, P Joseph-Bravo.   

Abstract

TRH (pGlu-His-ProNH2) inactivation in the brain and pituitary extracellular fluid is reviewed. While TRH could be eliminated by alternative mechanisms, i.e. uptake or internalization, modification, hydrolysis by broad specificity peptidases such as pyroglutamyl peptidase I and prolyl endopeptidase, evidence accumulates to support a specific neuroectopeptidase as the main mechanism responsible for its extracellular inactivation. Pyroglutamyl peptidase II (PPII; E.C. 3.4.19.6) is a narrow specificity zinc metallopeptidase hydrolyzing the pyroglutamyl-histidyl peptide bond of TRH. PPII is an integral membrane protein with a small intracellular domain, a transmembrane segment and a large extracellular domain that contains the catalytic site. It is therefore idealy situated to degrade TRH present in the extracellular space. PPII is highly enriched in brain, specifically present in neuronal cells. PPII inhibition enhances recovery of TRH released in vitro. In situ hybridization studies demonstrate that PPII mRNA colocalizes with TRH-receptor mRNA in various brain regions. However, the existence of exceptions suggest that alternative inactivation mechanisms for TRH may operate. PPII activity is regulated in various pharmacological or pathophysiological conditions which alter TRH transmission. It is also present in adenohypophysis, preferentially on lactotrophs, where its activity is stringently regulated by hormones and hypothalamic factors. PPII activity regulation may contribute to adjust TRH neural and hormonal transmissions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9713831

Source DB:  PubMed          Journal:  Neurobiology (Bp)        ISSN: 1216-8068


  8 in total

Review 1.  Central regulation of hypothalamic-pituitary-thyroid axis under physiological and pathophysiological conditions.

Authors:  Csaba Fekete; Ronald M Lechan
Journal:  Endocr Rev       Date:  2013-12-13       Impact factor: 19.871

2.  Regulation of adenohypophyseal pyroglutamyl aminopeptidase II activity by thyrotropin-releasing hormone and phorbol esters.

Authors:  M A Vargas; M Cisneros; P Joseph-Bravo; J L Charli
Journal:  Endocrine       Date:  2000-12       Impact factor: 3.633

3.  Three TRH-like molecules are released from rat hypothalamus in vitro.

Authors:  M Méndez; M Cisneros; A Baez; P Joseph-Bravo; J L Charli
Journal:  Neurochem Res       Date:  1999-07       Impact factor: 3.996

4.  Thyroxine-induced expression of pyroglutamyl peptidase II and inhibition of TSH release precedes suppression of TRH mRNA and requires type 2 deiodinase.

Authors:  Alessandro Marsili; Edith Sanchez; Praful Singru; John W Harney; Ann Marie Zavacki; Ronald M Lechan; P R Larsen
Journal:  J Endocrinol       Date:  2011-07-25       Impact factor: 4.286

Review 5.  Minireview: The neural regulation of the hypothalamic-pituitary-thyroid axis.

Authors:  Ricardo H Costa-e-Sousa; Anthony N Hollenberg
Journal:  Endocrinology       Date:  2012-07-03       Impact factor: 4.736

6.  Tanycyte pyroglutamyl peptidase II contributes to regulation of the hypothalamic-pituitary-thyroid axis through glial-axonal associations in the median eminence.

Authors:  Edith Sánchez; Miguel Angel Vargas; Praful S Singru; Isel Pascual; Fidelia Romero; Csaba Fekete; Jean-Louis Charli; Ronald M Lechan
Journal:  Endocrinology       Date:  2009-01-29       Impact factor: 4.736

7.  Stage-specific modulation of neprilysin and aminopeptidase N in the limbic system during kindling progression.

Authors:  Patricia de Gortari; Miguel Angel Vargas; Adrián Martínez; Arlene I García-Vázquez; Rosa María Uribe; Lucía Chávez-Gutiérrez; Víctor Magdaleno; Guy Boileau; Jean-Louis Charlí; Patricia Joseph-Bravo
Journal:  J Mol Neurosci       Date:  2007-04-17       Impact factor: 3.444

Review 8.  The Thyrotropin-Releasing Hormone-Degrading Ectoenzyme, a Therapeutic Target?

Authors:  Jean-Louis Charli; Adair Rodríguez-Rodríguez; Karina Hernández-Ortega; Antonieta Cote-Vélez; Rosa María Uribe; Lorraine Jaimes-Hoy; Patricia Joseph-Bravo
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.